Discover how Ergomed facilitated access to a Phase II/III Clinical Trial for Primary Hyperoxaluria (PH), an ultra-rare metabolic disorder, by ensuring a 5-year-old refugee patient from North Africa could participate in the study from Barcelona.
This case study highlights Ergomed’s coordinated efforts in overcoming logistical and language barriers, including translation, interpretation, and direct-to-home medication delivery.
Download the full case study to learn how Ergomed’s tailored solutions make cross-border trials accessible and patient-centered, supporting success in rare disease research.
